Signals, Powered By EquityPandit
The prices of 51 essential formulations, including those used for the treatment of cancer, kidney diseases, cardiac and skin problems has been capped by national drug pricing regulator, NPPA.
The prices of these formulations has been lowered in the range of 6 to 53%. NPPA in a separate notification has notified ceiling prices of 13 formulations, and has revised the same for 15 formulations. Further, it has also notified retail prices of 23 essential formulations.
Ceiling prices of drugs which have been capped includes colon or rectal cancer treatment drug oxaliplatin (injection 100mg), Japanese encephalitis vaccine and measles rubbela vaccine, while drugs whose ceiling prices have been revised includes anesthetic sevoflurane, Phytomenadione (Vitamin K1) and tuberculosis prevention medicine BCG vaccine.
